FOXK2 affects the motility of endometrial cancer cells by mediating ZEB1

Endometrial cancer (EC) is a prevalent type of malignancy, highlighting the need for the development of effective therapies and the identification of novel therapeutic targets. FOXK2, a member of the Foxhead box (FOX) family, has been implicated in cancer progression. However, the role of FOXK2 in EC and its underlying mechanisms remain poorly understood. This study investigates the function of FOXK2 in EC. FOXK2 is significantly overexpressed in EC tissues. Knockdown of FOXK2 impedes the proliferation of EC cells and inhibits their motility and epithelial-mesenchymal transition (EMT). Mechanistically, FOXK2 depletion disrupts EC progression by targeting Zinc Finger E-Box Binding Homeobox 1 (ZEB1). In conclusion, FOXK2 regulates EC cell progression through modulation of ZEB1.

Foxhead box K2 (FOXK2); Endometrial cancer (EC); Motility; EMT; ZEB1

[1] Costas L, Onieva I, Pelegrina B, Marin F, Carmona Á, López-Querol M, et al. Evaluation of somatic mutations in urine samples as a non-invasive method for the detection and molecular classification of endometrial cancer. Clinical Cancer Research. 2023; 29: 3681–3690.

[2] Ma L, Huang W, Liang X, Bai G, Wang X, Jiang H, et al. Inhibition of squalene epoxidase linking with PI3K/AKT signaling pathway suppresses endometrial cancer. Cancer Science. 2023; 114: 3695–3607.

[3] Åkesson Å, Adok C, Dahm-Kähler P. Recurrence and survival in endometrioid endometrial cancer—a population-based cohort study. Gynecologic Oncology. 2023; 168: 127–134.

[4] Kang T, Liu N, Sun X, Liu M. Efficacy of postoperative radiotherapy combined with taxol+carboplatin chemotherapy regimens in the treatment of high-risk early-stage endometrial cancer. JBUON. 2021; 26: 561–568.

[5] Nestal de Moraes G, Carneiro LDT, Maia RC, Lam EW, Sharrocks AD. FOXK2 transcription factor and its emerging roles in cancer. Cancers. 2019; 11: 393.

[6] Liu X, Wei X, Niu W, Wang D, Wang B, Zhuang H. Downregulation of FOXK2 is associated with poor prognosis in patients with gastric cancer. Molecular Medicine Reports. 2018; 18: 4356–4364.

[7] Nestal de Moraes G, Ji Z, Fan LY, Yao S, Zona S, Sharrocks AD, et al. SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells. Carcinogenesis. 2018; 7: 29.

[8] Zhang Y, Wang Y, Zhao G, Tanner EJ, Adli M, Matei D. FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway. Journal of Clinical Investigation. 2022; 132: e151591.

[9] Du F, Qiao C, Li X, Chen Z, liu H, Wu S, et al. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR. Theranostics. 2019; 9: 3879–3902.

[10] Li S, Wang P, Ju H, Zhu T, Shi J, Huang Y. FOXK2 promotes the proliferation of papillary thyroid cancer cell by down-regulating autophagy. Journal of Cancer. 2022; 13: 858–868.

[11] López-Moncada F, Castellón EA, Contreras HR. The transcription factors Zeb1 and snail induce cell malignancy and cancer stem cell phenotype in prostate cells, increasing androgen synthesis capacity and therapy resistance. Advances in Experimental Medicine and Biology. 2022; 45: 51–64.

[12] Mohammadpour S, Esfahani AT, Khorasaniasl S, Karimpour R, Bakhshian F, Moradi A, et al. High expression of ZEB1 is associated with EMAST & metastasis in colorectal cancer patients. Indian Journal of Medical Research. 2022; 156: 64–69.

[13] Mei Y, Xu J, Li W, Chen S. Gambogic acid improves cisplatin resistance of bladder cancer cells through the epithelial-mesenchymal transition pathway mediated by the miR-205-5p/ZEB1 axis. Annals of Clinical & Laboratory Science. 2024; 54: 354–362.

[14] Xiao YY, Lin L, Li YH, Jiang HP, Zhu LT, Deng YR, et al. ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription. American Journal of Cancer Research. 2019; 9: 2314–2330.

[15] Gao Y, Gao J. Expression and clinical significance of KDM5A, KDM5B, and FOXO1 in endometrial cancer. Polish Journal of Pathology. 2024; 75: 83–96.

[16] Tachibana M, Nogami M, Inoue J, Zeng FB, Kubo K, Kurimoto T, et al. Time-synchronized 2-deoxy-2-[18F]fluoro-D-glucose PET/MRI with MR-active trigger and Bayesian penalized likelihood reconstruction: diagnostic utility for locoregional extension of endometrial cancer. European Journal of Radiology. 2024; 179: 111678.

[17] Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, et al. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. European Journal of Gynaecological Oncology. 2023; 44: 17–25.

[18] Wassel M, Hamdy D, Elghazawy R. Evaluation of four vital pulp therapies for primary molars using a dual-cured tricalcium silicate (TheraCal PT): one-year results of a non-randomized clinical trial. Journal of Clinical Pediatric Dentistry. 2023; 47: 10–22.

[19] Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Critical Reviews in Oncology/Hematology. 2006; 58: 242–256.

[20] Sukonina V, Ma H, Zhang W, Bartesaghi S, Subhash S, Heglind M, et al. FOXK1 and FOXK2 regulate aerobic glycolysis. Nature. 2019; 566: 279–283.

[21] Liu Y, Ao X, Jia Z, Bai XY, Xu Z, Hu G, et al. FOXK2 transcription factor suppresses ERalpha-positive breast cancer cell growth through down-regulating the stability of ERalpha via mechanism involving BRCA1/BARD1. Scientific Reports. 2015; 5: 8796.

[22] Ji Z, Mohammed H, Webber A, Ridsdale J, Han N, Carroll JS, et al. The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex. Nucleic Acids Research. 2014; 42: 6232–6242.

[23] Shan L, Zhou X, Liu X, Wang Y, Su D, Hou Y, et al. FOXK2 elicits massive transcription repression and suppresses the hypoxic response and breast cancer carcinogenesis. Cancer Cell. 2016; 30: 708–722.

[24] Chen S, Jiang S, Hu F, Xu Y, Wang T, Mei Q. Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes. Oncology Reports. 2017; 37: 2335–2347.